NCT02933775 - CD19-redirected Autologous Cells (CAR-CD19 T Cells) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

January 31, 2020

Conditions

CD19 Positive Malignant B-cell Leukemia and Lymphoma

Interventions

GENETIC

CAR-CD19 T cells

Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.

DRUG

Fludarabine

30 mg/m\^2/day×4 days

DRUG

Cyclophosphamide

500 mg/m\^2/day×2 days

Trial Locations (1)

200127

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai